EXIT071 develops a proprietary microfluidic technology, dzITP, for the efficient isolation and characterization of exosomes from various biological samples. This technology enables high-throughput biomarker discovery for non-invasive diagnostics and therapeutic applications, addressing the need for reliable cellular communication analysis in medical research.
Funding
$397.4K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for isolating and characterizing exosomes from biological samples are often inefficient and lack the ability to effectively separate exosomes from impurities. This makes high-throughput biomarker discovery challenging, hindering the development of non-invasive diagnostics and therapeutics.
Solution
EXIT071 offers a microfluidic technology, dzITP, designed for the efficient isolation and characterization of exosomes. The technology leverages electrophoretic mobility to separate and quantify exosomes from various biological samples in a single procedure, while also quantifying impurities. This integrated and automated platform enables high-quality biomarker discovery in a high-throughput format by connecting exosome isolation with molecular analysis techniques such as metabolomics, lipidomics, proteomics, and transcriptomics. The dzITP technology enriches, separates, and filters exosomes from complex samples, facilitating downstream analysis.
Target Audience
The primary target audience includes researchers and pharmaceutical companies involved in exosome research, biomarker discovery, non-invasive diagnostics development, and novel therapeutics.
Features
- Proprietary dzITP microfluidic technology for exosome isolation and characterization
- Electrophoretic mobility-based separation for high purity
- Simultaneous exosome isolation and impurity quantification
- Integrated platform for metabolomics, lipidomics, proteomics, and transcriptomics analysis
- High-throughput biomarker discovery capabilities
- Automated platform for efficient processing